O-RAN-ALLIANCE-E.V.
16.3.2021 12:30:05 CET | Business Wire | Press release
As of February 23, 2021, the O-RAN ALLIANCE welcomes DISH Network as a new member of its Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210316005553/en/
“Carriers around the world are recognizing the importance of building next-generation, programmable networks that are open, intelligent and flexible, making the work of the O-RAN ALLIANCE more critical than ever,” said Sidd Chenumolu, DISH vice president of technology development. “At DISH, we are in a unique position as we build a 5G network entirely upon O-RAN standards, and the work of this organization creates a unified roadmap as our partners join us in developing a disaggregated and open RAN. We look forward to playing a continued role in the success of the O-RAN ALLIANCE and the development of standards that enhance connectivity worldwide.”
O-RAN ALLIANCE’s Minimum Viable Plan (MVP) Towards Commercial O-RAN Solutions
O-RAN’s specification effort, open software development, as well as testing and integration, will focus on priorities set by its operator members. This approach will allow the O-RAN ecosystem players to prioritize the delivery of a minimum viable set of end-to-end O-RAN solutions applicable in commercial networks.
The first release of the MVP includes already published specifications and additional work items in the area of:
- Open fronthaul specifications provide fully specified control, user and synchronization interface, management plane interface between O-RU and O-DU, and relevant conformance and interoperability tests, enabling multi-vendor interoperability.
- Open transport defines the requirements of xhaul transport, proposes the best practices of deploying WDM and IP technologies in xhaul.
- Open hardware offers hardware reference designs for different modes of indoor picocell, outdoor microcell, outdoor Macrocell and open fronthaul gateway to accelerate the use of whitebox and facilitate RAN ecosystem diversity.
- Open stack provides a software reference design for O-CU/O-DU architecture, interfaces, internal modules, and APIs, to promote and guide the open source software development.
- Open cloud presents O-Cloud reference design with the fundamental synchronization requirements and real life deployment recommendations.
- Testing and integration sets the criteria and guidelines for the formation of Open Testing and Integration Centers (OTICs) , ensuring consistency and quality of the testing of O-RAN products and solutions.
Subsequent O-RAN releases will extend the MVP with additional features and functionalities based on continuing surveys and updates of operators’ deployment priorities.
28 New or Updated O-RAN Specifications Released since November 2020
On February 26, 2021, the O-RAN ALLIANCE published another 28 specification documents, including 10 new titles. For more details on the new specifications, please check this O-RAN blog post . To download O-RAN specifications, please proceed to www.o-ran.org/specifications .
O-RAN Open Summit Held on February 25, 2021 Available for Re-play
The O-RAN Open Summit on February 25, 2021 has gained attention with more than 2500 global visitors. The recording of Open Summit is available at the O-RAN website . The recording includes full content of the event, including five keynotes:
- Opening address - Alex Jinsung Choi , COO of O-RAN ALLIANCE and SVP Technology Strategy & Innovation of Deutsche Telekom
- Chairman address - Andre Fuetsch , Chairman of the O-RAN ALLIANCE and Chief Technology Officer of AT&T
- O-RAN Technical progress - Chih-Lin I , Co-Chair of O-RAN Technical Steering Committee and China Mobile Chief Scientist, Wireless Technologies, China Mobile Research Institute
- Testing and Integration Focus Group update - David Orloff , Co-chair of O-RAN Testing and Integration Focus Group, AT&T
- O-RAN Software Community update - Jack Murray , Co-Chair of OSC Technical Oversight Committee, AT&T
The event recording also includes the panel discussion on ‘Paths to O-RAN implementation ’ providing valuable insights on possible ways towards open RAN introduction in the public mobile networks. The panelists represent a great variety of players in the O-RAN ecosystem: AT&T, NTT DOCOMO, Orange, TIM, O-RAN ALLIANCE, Intel, Keysight, ONF, Nokia and Radisys.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 270 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN standards will enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks will at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information please visit www.o-ran.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005553/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom